MASLD

1
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sagimet Biosciences
Sagimet BiosciencesCA - San Mateo
1 program
1
denifanstatPhase 3Small Molecule1 trial
Active Trials
NCT06692283WithdrawnEst. Jun 2027

Trial Timeline

Clinical trial activity over time

2025
2026
2027
Sagimet Biosciencesdenifanstat

Clinical Trials (1)

A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH

Start: Mar 2025Est. completion: Jun 2027
Phase 3Withdrawn

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space